ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients

Molecular Oncology

Volumn 8, Issue 1, 2014, Pages 142-149

  Ajani, J A ^a   Wang, X ^a   Song, S ^a   Suzuki, A ^a   Taketa, T ^a   Sudo, K ^a   Wadhwa, R ^a   Hofstetter, W L ^a   Komaki, R ^a   Maru, D M ^a   Lee, J H ^a   Bhutani, M S ^a   Weston, B ^a   Baladandayuthapani, V ^a   Yao, Y ^a   Honjo, S ^a   Scott, A W ^a   Skinner, H D ^a   Johnson, R L ^a   Berry, D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ALDH 1; Chemotherapy resistance; Esophageal carcinoma; Predictive markers; Prognosis; Radiation resistance

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; FLUOROPYRIMIDINE; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CHEMORADIOTHERAPY; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHENOTYPE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR GENE; VALIDATION STUDY; VERY ELDERLY;

ALDH-1; CHEMOTHERAPY RESISTANCE; ESOPHAGEAL CARCINOMA; PREDICTIVE MARKERS; PROGNOSIS; RADIATION RESISTANCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MIDDLE AGED; PROGNOSIS; RETINAL DEHYDROGENASE;

EID: 84893006227     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.10.007     Document Type: Article

References (34)

1. Ajani J.A., Barthel J.S., Bentrem D.J., et al. Esophageal and esophagogastric junction cancers. J. Natl. Compr. Canc Netw. 2011, 9:830-887.
2. Ajani J.A., Correa A.M., Hofstetter W.L., et al. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann. Oncol. 2012, 23:2638-2642.
3. Allum W.H., Stenning S.P., Bancewicz J., Clark P.I., Langley R.E. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J. Clin. Oncol. 2009, 27:5062-5067.
4. Awad O., Yustein J.T., Shah P., et al. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS ONE 2010, 5:e13943.
5. Brennan S.K., Meade B., Wang Q., Merchant A.A., Kowalski J., Matsui W. Mantle cell lymphoma activation enhances bortezomib sensitivity. Blood 2010, 116:4185-4191.
6. Cheedella N.K., Suzuki A., Xiao L., et al. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann. Oncol. 2012, 24:1262-1266.
7. Chirieac L.R., Swisher S.G., Ajani J.A., et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005, 103:1347-1355.
8. Ginestier C., Hur M.H., Charafe-Jauffret E., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Null. 2007, 1:555-567.
9. Harrell F.E. Regression Modeling Strategies 2001, Springer-Verlag, New York.
10. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
11. Jiang F., Qiu Q., Khanna A., et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol. Cancer Res. 2009, 7:330-338.
12. Kelsen D.P., Ginsberg R., Pajak T.F., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N. Engl. J. Med. 1998, 339:1979-1984.
13. Kim M.P., Fleming J.B., Wang H.M., et al. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS ONE 2011, 6.
14. Moreb J.S., Baker H.V., Chang L.J., et al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol. Cancer 2008, 7:87.
15. Nguyen G.H., Murph M.M., Chang J.Y. Cancer stem cell Radioresistance and enrichment: where frontline radiation therapy may fail in lung and esophageal cancers. Cancers (Basel) 2011, 3:1232-1252.
16. Nogami T., Shien T., Tanaka T., et al. Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1-3 lymph node metastases. Breast Cancer 2012, Epub ahead of print, PMID: 2247396.
17. Raju U., Ariga H., Koto M., et al. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Radiother. Oncol. 2006, 80:185-191.
18. Ricardo S., Vieira A.F., Gerhard R., et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J. Clin. Pathol. 2011, 64:937-946.
19. Rice T.W., Rusch V.W., Apperson-Hansen C., et al. Worldwide esophageal cancer collaboration. Dis. Esophagus 2009, 22:1-8.
20. Rizk N.P., Venkatraman E., Bains M.S., et al. American joint committee on cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J. Clin. Oncol. 2007, 25:507-512.
21. Rohatgi P., Swisher S.G., Correa A.M., et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 2005, 104:2365-2372.
22. Rohatgi P.R., Swisher S.G., Correa A.M., et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 2005, 104:1349-1355.
23. Sims-Mourtada J., Izzo J.G., Apisarnthanarax S., et al. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin. Cancer Res. 2006, 12:6565-6572.
24. Sims-Mourtada J., Izzo J.G., Ajani J., Chao K.S. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 2007, 26:5674-5679.
25. Soldes O.S., Kuick R.D., Thompson I.A., et al. Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas. Br. J. Cancer 1999, 79:595-603.
26. Song S., Mazurek N., Liu C., et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res. 2009, 69:1343-1349.
27. Song S., Maru D.M., Ajani J.A., et al. Loss of TGF-beta adaptor beta2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. Cancer Res. 2013, 73:2159-2169.
28. Steg A.D., Bevis K.S., Katre A.A., et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin. Cancer Res. 2012, 18:869-881.
29. Thrift A.P., Whiteman D.C. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann. Oncol. 2012, 23:3155-3162.
30. van Hagen P., Hulshof M.C., van Lanschot J.J., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 2012, 366:2074-2084.
31. Wang Y.C., Yo Y.T., Lee H.Y., et al. ALDH1-Bright Epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am. J. Pathol. 2012, 180:1159-1169.
32. Wang Y., Zhe H., Gao P., Zhang N., Li G., Qin J. Cancer stem cell marker ALDH1 expression is associated with lymph node metastasis and poor survival in esophageal squamous cell carcinoma: a study from high incidence area of northern China. Dis. Esophagus 2012, 25:560-565.
33. Wu T.T., Chirieac L.R., Abraham S.C., et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am. J. Surg. Pathol. 2007, 31:58-64.
34. Zhang G., Ma L., Xie Y.K., Miao X.B., Jin C. Esophageal cancer tumorspheres involve cancer stem-like populations with elevated aldehyde dehydrogenase enzymatic activity. Mol. Med. Rep. 2012, 6:519-524.